The landscape for IP protection in the United States has shifted significantly in the wake of lobbying, changes in federal laws, and precedential decisions from the Supreme Court and Federal Circuit. Many of these changes are in response to litigation practices used by non-practicing entities. Alper will discuss key changes to the laws governing patent and trade secret protection and how they affect IP strategy for developed and emerging companies in the biotech space.
Alper Ertas, Counsel, Venable LLP
Visit The Bio2Device Group for more information about this event.